PT-141

They act on different systems. PT-141 activates melanocortin receptors, including ones in the central nervous system, and it was approved on trial results for sexual desire in premenopausal women. Viagra and other PDE5 inhibitors increase blood flow to the genitals to support an erection and don't act on desire directly. The Vyleesi label says the exact mechanism behind PT-141's effect on desire is unknown, and no trial has compared the two drugs head to head.

As of October 2026, bremelanotide is FDA-approved only as Vyleesi, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The label says it isn't indicated for men, for postmenopausal women, or to enhance sexual performance. In men, the evidence is Phase 2 only and used a nasal spray. A Phase 2B trial in 726 men with erectile dysfunction found better erectile function scores than placebo at doses of 7.5 mg and above, but up to 53% of men on the highest dose dropped out, mostly because of nausea, vomiting or blood pressure rises. A 2008 trial in 342 men who hadn't responded to sildenafil reported benefit in 33.5% vs 8.5% on placebo, but that paper has carried an expression of concern from its journal since 2023. The developer dropped the nasal form as a first-line treatment over blood pressure rises and variable blood levels. Many men use PT-141 for erectile dysfunction or libido anyway; that use rests on these Phase 2 data and user reports, not an approval. Talk to a healthcare professional about approved options.

The Vyleesi label calls for a dose at least 45 minutes before sexual activity and says the duration of effect after each dose is unknown and the best timing hasn't been fully characterized. Its half-life is about 2.7 hours. Vendor and community guides describe noticing effects within 1-2 hours, a peak at 2-4 hours, and effects lasting 6-12 hours; these are user reports that vary widely between people, and we couldn't find a study that measured them.

Nausea. In the Phase 3 trials, 40% of women had it, usually starting within an hour of the dose and lasting about two hours; 13% needed anti-nausea medicine and 8% stopped treatment. It improved for most by the second dose. Users commonly describe starting with a small test dose (0.25-0.5 mg) to gauge nausea, but that practice hasn't been tested in trials. With frequent use, skin darkening is the other risk to know about: the label reports it in 38% of women who dosed daily for 8 days, and it didn't always fade after stopping. Talk to a healthcare professional before using it.

You need to be cautious. In trials, each dose raised blood pressure by up to 6/3 mmHg, peaking 2-4 hours after injection, and lowered heart rate by up to 5 beats per minute; both usually returned to baseline within 12 hours. The Vyleesi label lists uncontrolled hypertension and known cardiovascular disease as contraindications and doesn't recommend it for people at high cardiovascular risk. If you have high blood pressure or heart disease, you should avoid it or consult with a qualified healthcare professional before use.